PARSIPPANY, NJ--(Marketwire - September 16, 2009) - The Medicines Company (NASDAQ: MDCO) is scheduled to participate in the UBS Global Life Sciences Conference on Wednesday, September 23rd, 2009. John Kelley, President and Chief Operating Officer, will present at 9:00am Eastern Time. A company overview will be provided in the presentation.
The session will be webcast with a link available at The Medicines Company's website: http://www.themedicinescompany.com.
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment
of critical care patients through the delivery of innovative,
cost-effective medicines to the worldwide hospital marketplace. The Company
markets Angiomax® (bivalirudin) in the United States and other countries
for use in patients undergoing coronary angioplasty, and Cleviprex®
(clevidipine butyrate) injectable emulsion in the United States for the
reduction of blood pressure when oral therapy is not feasible or not
desirable. The Medicines Company's website is www.themedicinescompany.com.
Contact:
Robyn Brown
Vice President, Investor Relations
The Medicines Company
973-290-6000
investor.relations@themedco.com
